铁死亡在急性心肌梗死后心室重构中的研究进展

doi:10.16352/j.issn.1001-6325.2026.03.0440

基础医学与临床 ›› 2026, Vol. 46 ›› Issue (3): 440-444.doi: 10.16352/j.issn.1001-6325.2026.03.0440

铁死亡在急性心肌梗死后心室重构中的研究进展

古丽胡马·阿不都克然木, 迪丽达尔·希力甫, 阿迪拉·阿扎提^*

新疆医科大学第一附属医院心血管内科,新疆乌鲁木齐 830054

收稿日期:2025-06-24 修回日期:2025-09-24 出版日期:2026-03-05 发布日期:2026-02-25
通讯作者: ^*adlndl@163.com
基金资助:
新疆维吾尔自治区科技厅上合国际项目(2022E01037)

Progress of ferroptosis in ventricular remodeling after acute myocardial infarction

Gulihuma·ABUDUKERANMU, Dilidaer·XILIFU, Adila·AZHATI^*

Department of Cardiology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China

Received:2025-06-24 Revised:2025-09-24 Online:2026-03-05 Published:2026-02-25
Contact: ^*adlndl@163.com

摘要/Abstract

摘要： 铁死亡是一种新型铁依赖性细胞死亡方式,近年来在急性心肌梗死(AMI)后心室重构中的作用备受关注。研究发现,AMI后心肌缺血、缺氧、铁超载及氧化应激可激活铁死亡通路,通过谷胱甘肽过氧化物酶4(GPX4)失活、脂质活性氧(ROS)累积等机制,导致心肌细胞死亡和间质纤维化,从而促进心室重构的发生。动物模型证实,铁死亡抑制剂可减轻心肌损伤并改善心室重塑。综上,抑制铁死亡有望成为未来防治AMI后心室重构的新的治疗思路。

关键词: 铁死亡, 心肌梗死, 心室重塑, 心力衰竭

Abstract: Ferroptosis is a new type of iron-dependent cell death, and its role in ventricular remodeling after acute myocardial infarction has attracted much attention in recent years. Studies have found that myocardial ischemia,hypoxia, iron overload and oxidative stress after AMI can activate the ferroptosis pathway, leading to cardiomyocyte death and interstitial fibrosis through mechanisms such as glutathione peroxidase 4 (GPX4) inactivation and lipid reactive oxygen species (ROS) accumulation, thereby promoting ventricular remodeling. Researches with animal models have confirmed that ferroptosis inhibitors or iron chelators can reduce myocardial injury and improve ventricular remodeling. In summary, inhibition of ferroptosis is expected to become a new strategy for the prevention and treatment of ventricular remodeling after AMI in the future.

Key words: ferroptosis, myocardial infarction, ventricular remodeling, heart failure

中图分类号:

R541

古丽胡马·阿不都克然木, 迪丽达尔·希力甫, 阿迪拉·阿扎提. 铁死亡在急性心肌梗死后心室重构中的研究进展[J]. 基础医学与临床, 2026, 46(3): 440-444.

Gulihuma·ABUDUKERANMU, Dilidaer·XILIFU, Adila·AZHATI. Progress of ferroptosis in ventricular remodeling after acute myocardial infarction[J]. Basic & Clinical Medicine, 2026, 46(3): 440-444.

参考文献

[1] Wang Z, Ding X, Pan J, et al. Iron in ventricular remodeling and aneurysms post-myocardial infarction[J]. Open Med (Wars), 2024, 19: 20241109.doi:10.1515/med-2024-1109.
[2] Komai K, Kawasaki NK, Higa JK, et al. The role of ferroptosis in adverse left ventricular remodeling following acute myocardial infarction[J]. Cells, 2022, 11.doi: 10.3390/cells11091399.
[3] Mayr A, Klug G, Reindl M, et al. Evolution of myocardial tissue injury: a CMR study over a decade after STEMI[J]. JACC Cardiovasc Imaging, 2022, 15: 1030-1042.doi: 10.1016/j.jcmg.2022.02.010.
[4] Zhang Y, Xin L, Xiang M, et al. The molecular mechanisms of ferroptosis and its role in cardiovascular disease[J]. Biomed Pharmacother, 2022, 145: 112423.doi: 10.1016/j.biopha.2021.112423.
[5] Guo Y, Lu C, Hu K, et al. Ferroptosis in cardiovascular diseases: current status, challenges, and future perspectives[J]. Biomolecules, 2022, 12.doi: 10.3390/biom12030390.
[6] Li FJ, Long HZ, Zhou ZW, et al. System X(c) (-)/GSH/GPX4 axis: an important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy[J]. Front Pharmacol, 2022, 13: 910292. doi:10.3389/fphar.2022.910292.
[7] Zhang Z, Yang Z, Wang S, et al. Decoding ferroptosis: Revealing the hidden assassin behind cardiovascular diseases[J]. Biomed Pharmacother, 2024, 176: 116761.doi: 10.1016/j.biopha.2024.116761.
[8] Jin S, Wang H, Zhang X, et al. Emerging regulatory mechanisms in cardiovascular disease: ferroptosis[J]. Biomed Pharmacother, 2024, 174: 116457.doi: 10.1016/j.biopha.2024.116457.
[9] Fratta Pasini AM, Stranieri C, Busti F, et al. New insights into the role of ferroptosis in cardiovascular diseases[J]. Cells, 2023, 12.doi:10.3390/cells12060867.
[10] Zhang CH, Yan YJ, Luo Q. The molecular mechanisms and potential drug targets of ferroptosis in myocardial ischemia-reperfusion injury[J]. Life Sci, 2024, 340: 122439. doi:10.1016/j.lfs.2024.122439.
[11] Sharma J, Bhargava P, Mishra P, et al. Molecular mechanisms of flavonoids in myocardial ischemia reperfusion injury: evidence from in vitro and in vivo studies[J]. Vascul Pharmacol, 2024, 155: 107378.doi:10.1016/j.vph.2024.107378.
[12] Sun S, Shen J, Jiang J, et al. Targeting ferroptosis opens new avenues for the development of novel therapeutics[J]. Signal Transduct Target Ther, 2023, 8: 372.doi: 10.1038/s41392-023-01606-1.
[13] Wu C, Bao S, Sun H, et al. Noncoding RNAs regulating ferroptosis in cardiovascular diseases: novel roles and therapeutic strategies[J]. Mol Cell Biochem, 2024, 479: 2827-2841.doi: 10.1007/s11010-023-04895-w.
[14] Villarruz-Sulit MV, Forster R, Dans AL, et al. Chelation therapy for atherosclerotic cardiovascular disease[J]. Cochrane Database Syst Rev, 2020, 5: Cd002785.doi: 10.1002/14651858.CD002785.pub2.
[15] Song T, Zhang D. Evaluation on curative effects of ethylene diamine tetra-acetic acid chelation therapy in treating with atherosclerotic cardiovascular disease: a protocol for systematic review and Meta-analysis[J]. Medicine (Baltimore), 2020, 99: e23346.doi: 10.1097/md.0000000000023346.
[16] Huang C, Guo Y, Li T, et al. Pharmacological activation of GPX4 ameliorates doxorubicin-induced cardiomyopathy[J]. Redox Biol, 2024, 70: 103024. doi:10.1016/j.redox.2023.103024.
[17] Park TJ, Park JH, Lee GS, et al. Quantitative proteomic analyses reveal that GPX4 downregulation during myocardial infarction contributes to ferroptosis in cardiomyocytes[J]. Cell Death Dis, 2019, 10: 835. doi:10.1038/s41419-019-2061-8.
[18] Shen C, Wei Y, Kang W, et al. Persistent ferroptosis modulates cardiac remodeling and M2 macrophage polarization, which can be mitigated by astaxanthin during myocardial infarction recovery[J]. Cardiovasc Toxicol, 2025, 25: 58-73.doi:10.1007/s12012-024-09942-6.
[19] Chen Y, Li X, Wang S, et al. Targeting iron metabolism and ferroptosis as novel therapeutic approaches in cardiovascular diseases[J]. Nutrients, 2023, 15.doi: 10.3390/nu15030591.
[20] Yeang C, Hasanally D, Que X, et al. Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids[J]. Cardiovasc Res, 2019, 115: 179-189.doi: 10.1093/cvr/cvy136.
[21] Violi F, Nocella C, Loffredo L, et al. Interventional study with vitamin E in cardiovascular disease and meta-analysis[J]. Free Radic Biol Med, 2022, 178: 26-41.doi: 10.1016/j.freeradbiomed.2021.11.027.
[22] Gu H, Liu J, Jiang J, et al. The role of Nrf2 signaling pathway in diabetic cardiomyopathy: from pathogenesis to traditional Chinese medicine interventions[J]. Front Cardiovasc Med, 2025, 12: 1492499.doi:10.3389/fcvm.2025.1492499.

铁死亡在急性心肌梗死后心室重构中的研究进展

Progress of ferroptosis in ventricular remodeling after acute myocardial infarction

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐霞, 王富兵, 赵培培, 范辉, 李欣, 张谷, 顾新红. 大株红景天注射液对非酒精性脂肪性肝病模型大鼠的治疗作用[J]. 基础医学与临床, 2026, 46(3): 367-373.
[2]	徐伯鑫, 山媛, 杨云鹏. D-松醇缓解脑缺血/再灌注模型大鼠的脑损伤[J]. 基础医学与临床, 2026, 46(3): 359-366.
[3]	吴慧琳, 袁芳. 铁死亡在血管钙化疾病中的作用[J]. 基础医学与临床, 2026, 46(3): 456-461.
[4]	李静薇, 张润峰. 利拉鲁肽降低心肌梗死大鼠心功能损伤及房颤易感性[J]. 基础医学与临床, 2026, 46(2): 193-199.
[5]	张玉锋, 张新娜, 周艳娇. PHLPP2变异和EGFR+TP53共突变与晚期肺腺癌预后及铁死亡相关[J]. 基础医学与临床, 2026, 46(1): 103-108.
[6]	邸涛, 邵凯, 梁洁, 王晓昭. 替奈普酶联合替罗非班在急性心肌梗死介入治疗中的应用[J]. 基础医学与临床, 2025, 45(9): 1215-1219.
[7]	薛雅馨, 陈安琪, 郑懿, 蓝云云. 联合检测血清sST2、GFR和SI对急性失代偿性心力衰竭患者预后的预测[J]. 基础医学与临床, 2025, 45(9): 1184-1189.
[8]	武波, 郭昊, 钟曌, 刘军芳, 王琦, 郭继勃. 过表达miR-101抑制JAK2/STAT3信号通路减缓急性心肌梗死模型大鼠心室重构[J]. 基础医学与临床, 2025, 45(3): 281-289.
[9]	刘甜娜, 李阳, 邓雨笛, 吴富菊. Poly(C)-结合蛋白1在铁死亡中的研究进展[J]. 基础医学与临床, 2025, 45(11): 1501-1505.
[10]	李文华, 王润霖, 康乾鹏, 黄梅, 郭正光, 张春林, 黄永胜. p97抑制剂EerⅠ诱导胃癌细胞系AGS的凋亡与铁死亡[J]. 基础医学与临床, 2025, 45(11): 1401-1408.
[11]	付淼, 刘蓬, 田文, 王莎, 尹晓梅, 刘昊, 王东海. METTL3通过介导TRPM7甲基化调节宫颈癌细胞铁死亡和恶性进展[J]. 基础医学与临床, 2025, 45(10): 1318-1325.
[12]	肖艳红, 姜明东, 林叶远, 冉灿, 梁博. 灯盏花乙素抑制人前列腺癌细胞系PC-3的增殖和迁移[J]. 基础医学与临床, 2024, 44(9): 1229-1235.
[13]	胡川丽, 贺晓松, 赵江, 李华. 基于机器学习算法的心力衰竭预测模型[J]. 基础医学与临床, 2024, 44(6): 845-852.
[14]	杨洋, 张雅茸, 杨红琴, 王婧, 赵红梅. 磷酸二酯酶5在心力衰竭中作用的研究进展[J]. 基础医学与临床, 2024, 44(5): 724-728.
[15]	肖艳新, 刘岩, 许岭翎, 周亚茹. 铁死亡在非酒精性脂肪性肝病发病中作用的研究进展[J]. 基础医学与临床, 2024, 44(2): 260-264.